Time of maximum resolution of diabetic macular oedema after ranibizumab injection

Abstract EN

Introduction Macular edema occurs in a wide variety of ocular diseases, and an alteration in the blood–retinal barrier (BRB) leads to the accumulation of fluid in the extracellular space and the development of fluid-filled (cystoid) spaces in the outer plexiform layer and the inner nuclear layer of the retina are common findings in cystoid macular edema (CME)..

Aim of the Work : To evaluate the effect of intravitreal injection of ranibizumab on diabetic macular edema (DME).

Patients and Methods Type of the study :A longitudinal descriptive randomized study.- -Site of the study : The patients will be selected random from the outpatient clinic of National Eye Center of Opthamology in Rod El-Farag.

-Date and period of study : This study was conducted in March 2019.

-Size and type of sampling techniques to choose a representative sample: The study will include 20 eyes of 20 patients selected randomly with the following inclusion and exclusion criteria to receive a single intravitreal injection of ranibizumab.

- 20 eyes with Type II diabetes mellitus with non-proliferative diabetic retinopathy (NPDR) and significant focal or diffuse DME with no foveal serous detachment confirmed by OCT .

Results: Twenty eyes attending the ophthalmic outpatient clinic between March 2019 and December 2019 were selected.

They suffered focal or /and diffuse DME, All eyes received primary dose of intravitreal injection of ranibizumab (0.5 mg).

Conclusion : The study showed that most patients did not show significant improvement in V/A rather than a significant decrease in central macular thickness after one injection and the improvement was considered less than those patients who had received multiple injections in other studies.